Drug licensing deal brings millions in Israeli capital to Burnaby

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to ...

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to a pain drug that Xenon is developing.

The deal will see Teva pay Xenon $41 million up front, and then fund up to $335 million in “development, regulatory and sales-based milestones” for Xenon’s drug, XEN402. For its investment, Teva will obtain an exclusive worldwide license for the drug. Xenon will be entitled to royalties payable on sales and an option to participate in commercialization in the U.S.

Jeremy Levin, president and CEO of Teva, welcomed the deal.

“[This drug] holds the potential to address the significant unmet medical need for the many patients who suffer from chronic pain,” he said. “In addition, XEN402 has the potential for broader therapeutic use across other pain conditions.”

Simon Pimstone, president and CEO of Xenon, also expressed satisfaction with the deal.

“This partnership with Teva,” he said, “is Xenon’s seventh major pharmaceutical alliance, once again highlighting the value of Xenon’s unique genetics approach and translational R&D capabilities.”

The drug is currently in clinical development.

jwagler@biv.com

@JennyWagler_BIV

comments powered by Disqus

More from Technology

Nursing shortages spurs former video game developers into action

New app and virtual reality help health authorities train up new nurses amidst shortages

Read Article

U.S. military to test SFU-invented bionic exoskeletons

Bionic Power to help soldiers lighten load of carrying batteries

Read Article

B.C. firm lands Microsoft HoloLens program, ushers in augmented revenue reality

Finger Food Studios one of just eight global agencies — and the only one in Canada — selected for Microsoft’s augmented reality project

Read Article

BIV on Global BC July 15, 2016: Microsoft HoloLens, Canadian retail sales

Read Article

Deloitte joins Vandrico to increase employee efficiency with wearable tech

Vancouver based Vandrico has world's largest wearable tech database

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×